Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma	Active, not recruiting	Phase 2	2026-03-27		NCT03236428

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Blood Cancer Research Partnership	2
Dana-Farber Cancer Institute	324
Janssen Pharmaceuticals	24
Multiple Myeloma Research Consortium	9
The Leukemia and Lymphoma Society	22

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center	Boston	United States	462
Colorado Blood Cancer Institute	Denver	United States	178
Dana Farber Cancer Institute	Boston	United States	300
Karmanos Cancer Insitute	Detroit	United States	2
Massachusetts General Hospital	Boston	United States	21
Pacific Cancer Care	Monterey	United States	13